In summary, drug combination studies indicate that targeting EGFR in ESCC cells carrying EGFR copy number gain may negate or reduce anticancer effects of platinum-based chemotherapy; however, EGFR inhibitors are efficacious and synergistic in combination with docetaxel when scheduled correctly. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.